Catalyst

Slingshot members are tracking this event:

Flamel Technologies(FLML) targets filing an NDA for once-nightly sodium oxybate using Micropump technology in the first half of 2017

Source Link:
http://seekingalpha.com/article/3387765-flamel-technologies-flml-ceo-mike-anderson-on-q2-2015-results-earnings-call-transcript?page=2

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
FLML
100%
JAZZ
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Flamel has already met with the FDA to receive guidance for the pivotal trials and they were pleased with the FDA's direction.
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 01, 2018
Occurred Source:
http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-newsArticle&ID=2345923
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Sodium Oxybate, Xyrem, Narcolepsy, Micropump, Drug Delivery
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.